AKAhmet Kucuk

Ahmet Kucuk

*This is an algorithmically generated author record based on publicly available information.

Ahmet Kucuk has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pre-chemoradiotherapy high platelet counts predict jaw osteoradionecrosis in locally advanced nasopharyngeal carcinoma patients

    by Efsun Somay, Erkan Topkan, Ahmet Kucuk, Duriye Ozturk, Emine Elif Ozkan, Beyza Sirin Ozdemir, Ali Ayberk Besen, Huseyin Mertsoylu, Berrin Pehlivan, Ugur Selek


  • Open Access

    Prognostic Value of Novel CARWL Score in Stage IIIC Non‐Small‐Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy

    by Erkan Topkan, Ahmet Kucuk, Duriye Ozturk, Emine Elif Ozkan, Ali Ayberk Besen, Berrin Pehlivan, Ugur Selek

    Objectives. We explored the prognostic utility of the unique combination of C‐reactive‐protein‐to‐albumin ratio (CAR) and significant weight loss (WL > 5%) over the preceding 6 months, namely, the CARWL score, in stage IIIC non‐small‐cell lung cancer (NSCLC) patients who underwent concurrent chemoradiotherapy (CCRT). Methods. For each patient, the CAR was calculated using C‐reactive protein and albumin measurements obtained on the first day of CCRT: CAR = C‐reactive protein ÷ albumin. The availability of an ideal CAR cutoff that may categorize patients into two distinct progression‐free (PFS) and overall survival (OS) outcomes was explored by employing receiver operating characteristic (ROC) curve analysis. Patients were additionally divided into two groups based on their status of significant WL according to the well‐recognized Delphi criteria. Then, the CARWL score was created by combining all feasible combinations of the CAR and significant WL groupings. The potential links between pretreatment CARWL groups and the post‐CCRT OS and PFS outcomes were determined as the primary and secondary endpoints. Results. This retrospective cohort study comprised a total of 651 stage IIIC NSCLC patients. ROC curve analysis indicated that rounded 3.0 was the ideal CAR cutoff (area under the curve (AUC): 70.1%; sensitivity: 67.8%; specificity: 65.9%), which categorized the patients into CAR < 3.0 (N = 324) and CAR ≥ 3.0 (N = 327) groups. There were 308 (47.3%) and 343 (52.7%) patients without and with significant WL, respectively. The created CARWL groups were CARWL‐0: CAR < 3.0 and WL ≤ 5.0%; CARWL‐1: CAR < 3.0 and WL > 5.0%, or CAR ≥ 3.0 and WL ≤ 5.0%; and CARWL‐2: CAR > 3.0 and WL > 5.0%. The Kaplan–Meier curves showed that the PFS (14.2 vs. 11.4 vs. 7.5 months; P < 0.001) and OS (37.3 vs. 23.6 vs. 12.8 months; P < 0.001) durations were gradually and significantly lowered from the CARWL‐0 to CARWL‐2 groups. The CARWL score’s significant impacts on PFS and OS outcomes were found to be independent of the other variables in the multivariate analysis (P < 0.001, for each). Conclusions. Our findings indicate that the novel CARWL score, which accounts for pretreatment CAR and significant WL during the preceding 6 months, can reliably stratify newly diagnosed stage IIIC NSCLC patients into three groups with significantly different PFS and OS after definitive CCRT.


  • Utility of pre-chemoradiotherapy Pan-Immune-Inflammation-Value for predicting the osteoradionecrosis rates in locally advanced nasopharyngeal cancers

    by Busra Yilmaz, Efsun Somay, Erkan Topkan, Ahmet Kucuk, Berrin Pehlivan, Ugur Selek

    Purpose The aim of this retrospective study was to explore whether pretreatment Pan-Immune-Inflammation-Value (PIV) measurements might predict the risk of mandibular osteoradionecrosis (ORN) in patients receiving concurrent chemoradiotherapy (CCRT) for locally advanced nasopharyngeal cancer (LA-NPC). Methods The platelet, monocyte, neutrophil, and lymphocyte counts acquired on the first day of CCRT were used to compute pretreatment PIV levels: PIV = (Platelets × Monocytes × Neutrophils) ÷ Lymphocytes. Receiver operating characteristic curve analysis was used to determine the association between ORN rates and PIV levels. Spearman correlation analysis was used to examine the probable intergroup correlations. The potential link between the pretreatment PIV levels and the post-treatment ORN rates was determined as the primary objective. Results 21 (10.0%) of 210 eligible patients were diagnosed with ORN. The optimal pre-CCRT PIV cutoff was 833, which separated patients into two PIV groups with divergent ORN prevalence estimates: Group 1: PIV < 833 (N = 153), and Group 2: PIV ≥ 833 (N = 57). The comparison analysis found that the PIV ≥ 833 cohort had significantly higher ORN rates than the PIV < 833 cohort (29.8% vs. 2.6%; P < 0.001). Other characteristics linked to significantly higher ORN rates were the patient’s continuing smoking, the use of the Three-dimensional conformal radiation therapy technique, the mean mandibular dose of ≥ 58.1 Gy, the number of tooth extractions before CCRT ≥ 4, and the presence of tooth extractions after CCRT. The independent importance of all factors on higher ORN occurrence rates were retained in multivariate analysis (P < 0.05). Conclusions Our findings revealed a strong link between aggravated inflammatory response and ORN genesis, with high pretreatment PIV levels related to significantly higher ORN rates.


  • Top Cited Papers
    Open Access

    Review of Osteoradionecrosis of the Jaw: Radiotherapy Modality, Technique, and Dose as Risk Factors

    by Erkan Topkan, Ahmet Kucuk, Efsun Somay, Busra Yilmaz, Berrin Pehlivan, Ugur Selek

    Radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) is the cornerstone of organ-sparing or adjuvant therapy for nearly all head and neck cancers. Unfortunately, aggressive RT or CCRT can result in severe late toxicities, such as osteoradionecrosis of the jaws (ORNJ). The incidence of ORNJ is currently less than 5–6% due to advances in dental preventive care programs, RT planning systems, and RT techniques. Although numerous patient-, tumor-, and treatment-related factors may influence the incidence rates of ORNJ, RT modality (equipment), technique, and dose-volume-related factors are three of the most influential factors. This is mainly because different RT equipment and techniques have different levels of success at delivering the prescribed dose to the focal volume of the treatment while keeping the “organ at risk” safe. ORNJ risk is ultimately determined by mandibular dose, despite the RT technique and method being known predictors. Regardless of the photon delivery method, the radiobiological effects will be identical if the total dose, dose per fraction, and dose distribution within the tissue remain constant. Therefore, contemporary RT procedures mitigate this risk by reducing mandibular dosages rather than altering the ionizing radiation behavior in irradiated tissues. In light of the paucity of studies that have examined the impact of RT modality, technique, and dose-volume-related parameters, as well as their radiobiological bases, the present review aims to provide a comprehensive overview of the published literature on these specific issues to establish a common language among related disciplines and provide a more reliable comparison of research results.


  • Open Access

    The predictive value of pretreatment hemoglobin-to-platelet ratio on osteoradionecrosis incidence rates of locally advanced nasopharyngeal cancer patients managed with concurrent chemoradiotherapy

    by Busra Yilmaz, Efsun Somay, Erkan Topkan, Ahmet Kucuk, Berrin Pehlivan, Ugur Selek

    Background: This retrospective study aimed to investigate whether the pretreatment hemoglobin-to-platelet ratio (HPR) could predict the risk of osteoradionecrosis (ORN) in patients receiving concurrent chemoradiotherapy (C-CRT) for locally advanced nasopharyngeal carcinoma (LA-NPC). Methods: ORN cases were reported from the records of LA-NPC patients who had oral examinations before and after C-CRT. The pretreatment HPR values were calculated on the first day of C-CRT. The connection between HPR values and ORN occurrences was determined using receiver operating characteristic curve analysis. The primary endpoint was the relationship between the pretreatment HPR values and post-C-CRT ORN incidence rates, while secondary endpoints included the identification of other putative ORN risk factors. Results: We distinguished 10.9% incidences of ORN during the post-C-CRT follow-up period among 193 LA-NPC patients. The optimal cutoff for pre-C-CRT HPR was 0.48 that grouped the patients into two HPR groups with fundamentally different post-C-CRT ORN incidence rates: Group 1: HPR ≤ 0.48 (N = 60), and Group 2: HPR > 0.48 (N = 133). The comparative analysis indicated a significantly higher ORN incidence in HPR ≤ 0.48 group (30%; P < 0.001). The other factors associated with meaningfully increased ORN rates included the presence of pre-C-CRT ≥ 5 teeth extractions, mandibular volume receiving ≥ 64 Gy, post-C-CRT tooth extractions, mean mandibular dose ≥ 50.6 Gy, and C-CRT to tooth extraction interval > 5.5 months. Conclusion: Low pretreatment HPR levels were independently and unequivocally linked to significantly increased incidence of ORN post-C-CRT. Pre-C-CRT HPR levels may be used to estimate the incidence of ORN and be useful for taking preventive and therapeutic measures in these patients such as monitoring oral hygiene with strict follow-up, avoidance of unnecessary tooth extractions, particularly after C-CRT, and use of more rigorous mandibular RT dose limits.


  • Open Access

    Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide

    by Erkan Topkan, Ahmet Kucuk, Ugur Selek

    Objectives. The purpose of this study was to determine the predictive significance of pretreatment pan-immune-inflammation value (PIV) in patients with newly diagnosed glioblastoma multiforme (GBM) who received postsurgical radiation (RT) and concurrent plus adjuvant temozolomide (TMZ). Methods. The outcomes of 204 newly diagnosed GBM patients were analyzed retrospectively. Each eligible patient’s PIV was calculated using the findings of peripheral blood platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) counts obtained on the first day of therapy: . We used receiver operating characteristic (ROC) curve analysis to discover the ideal cutoff values for PIV concerning progression-free (PFS) and overall survival (OS) outcomes. The primary and secondary end-points were the OS and PFS divergences across the PIV groups. Results. In ROC curve analysis, the optimal PIV cutoff was 385, which substantially interacted with PFS and OS results and categorized patients into low PIV (L-PIV; ) and high PIV (H-PIV; ) groups. Comparative survival analyses showed that the patients in the H-PIV group had significantly shorter median PFS (6.0 vs. 16.6 months; ) and OS (11.1 vs. 22.9 months; ) durations than those in the L-PIV group. The results of multivariate Cox regression analysis indicated an independent and significant connection between an H-PIV measure and shorter PFS and OS outcomes. Conclusions. The novel PIV was able to independently stratify newly diagnosed GBM patients into two groups with fundamentally different PFS and OS outcomes following RT and concurrent plus adjuvant TMZ.


  • Open Access

    Importance of Novel Gastric Cancer Prognostic Index in Patients with Locally Advanced Gastric Cancer Who Underwent Radical Gastrectomy and Chemoradiotherapy

    by Ahmet Küçük, Düriye Öztürk, Hüseyin Pülat, Şükran Eskici Öztep, Recep Çağlar, Eda Bengi Yılmaz, Erkan Topkan

    Aim: To investigate the significance of the novel gastric cancer prognostic index, which combines albumin and metastatic lymph node count, on the outcomes of patients with locally advanced gastric cancer who received radical gastrectomy and concurrent chemoradiotherapy. Method: Patients who received concurrent chemoradiotherapy following radical gastrectomy between January 2014 and December 2019 were included in this retrospective analysis. According to the literature, the ideal cutoff value for albumin was determined to be 3.5 g/dL. Meanwhile, the optimal cutoff value for metastatic lymph node count was determined using receiver operating characteristic curve analysis. Results: This retrospective study comprised 137 locally advanced gastric cancer patients. The ideal albumin cutoff value was chosen to be the classically referred 3.5 g/dL (< 3.5 versus ≥ 3.5 g/dL), while the results of the receiver operating characteristic curve analysis revealed the ideal metastatic lymph node count cutoff value as 5 (< 5 versus ≥ 5). Hence, the study population was divided into four possible groups: Group 1: albumin ≥ 3.5 g/dL and metastatic lymph node count < 5, Group 2: albumin ≥ 3.5 g/dL and metastatic lymph node count ≥ 5, Group 3: albumin < 3.5 g/dL and metastatic lymph node count < 5, and Group 4: albumin < 3.5 g/dL and metastatic lymph node count ≥ 5. Since there was no significant difference between Group 2 and Group 3 in the analysis, they were combined to create gastric cancer prognostic index-2. The Kaplan-Meier curves revealed that gastric cancer prognostic index-1 and gastric cancer prognostic index-3 had significant differences in progression-free survival (66.0 versus 16.4 months; P < 0.001) and overall survival (66.0 versus 19.5 months, P < 0.001), respectively. The results of the multivariate analysis confirmed the gastric cancer prognostic index grouping’s independent prognostic significance for overall survival (P < 0.001) and progression-free survival (P = 0.05) outcomes. Conclusion: The novel gastric cancer prognostic index may be utilized as an independent and precise prognostic indicator.

  • Geriatrik Onkoloji

    by Ezgi Hacıhasanoğlu, Hatice Küçük, Emine Ülkü Akçay, Ayfer Altaş, Fatma Betül Asan, Aysel Toçoğlu, İrFan Esen, Ferhat Ekinci, Egemen Çiçek, Mesut Yur, et al.

    Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır. Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejileri sayesinde her hastaya özgü bir şekilde planlanmaktadır. Tedavilerin bireyselleştirilmesi hususunda kuşkusuz yaş faktörünün önemi büyüktür ve tedavi kararlarında geriatrik popülasyon için seçilecek tedavi modalitesinin belirlenmesi oldukça hassas bir konudur. Zira tedavi seçeneklerinin herbirinin geriatrik popülasyonda kullanım şemaları, yan etki dağılımları ve yönetimleri farklılıklar göstermekte olup günlük pratiğimizde azımsanmayacak sıklıkta karşılaştığımız problemlerdendir.